H1299 nsclc cells

H1299 NSCLC cells were obtained from ATCC (Manassas, VA, USA) and cultured in RPMI 1640 medium (#LM011–01; Welgene, Gyeongsangbuk-do, Republic of Korea) supplemented with 10% foetal bovine serum (Gibco; Thermo Fisher Scientific, Waltham, MA, USA). Metformin, phenformin and thiazolyl blue tetrazolium bromide (MTT) were purchased from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany).

βIII‐tubulin shRNA expressing cells (H460 βIII_SH4,59, and A549 βIII_SH61), stable control shRNA expressing cells (H460 βIII_SH1,2, and A549 βIII_SH27) and H460 βIII‐tubulin “rescue” cells (H460 βIII R6) were all developed and characterised as previously described.¹¹ The use of all genetically modified cell lines was done in accordance with the UNSW GMO notification system under Exempt Dealing 21–22. H1299 NSCLC cells were obtained from ATCC (ATCC, cat# CRL‐5803). All cell lines were validated by STR profiling at the Garvan Institute and were routinely tested and found to be free from mycoplasma contamination. Cells were maintained in RPMI‐1640 medium (Gibco, cat# A1049101), supplemented with 10% FBS, at 37°C and 5% CO₂. For routine maintenance, cells were cultured in T75 plastic cell culture flasks (Corning, cat# 430641U) and split via trypsinisation approximately every 3 days or when approaching confluence.